- Home
- LSBK vs QNCX Comparison
LSBK vs QNCX Comparison
Compare LSBK & QNCX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | LSBK | QNCX |
|---|---|---|
| Founded | 1891 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Savings Institutions | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 135.5M | 17.5M |
| IPO Year | 2025 | 2019 |
Fundamental Metrics
Financial Performance| Metric | LSBK | QNCX |
|---|---|---|
| Price | $17.87 | $29.67 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 2 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 24.3K | 14.9K |
| Earning Date | 04-22-2026 | 04-10-2026 |
| Dividend Yield | ★ 2.27% | N/A |
| EPS Growth | ★ 49.23 | N/A |
| EPS | ★ 0.56 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $31.82 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $12.50 | $0.08 |
| 52 Week High | $19.09 | $35.41 |
Technical Indicators
Market Signals| Indicator | LSBK | QNCX |
|---|---|---|
| Relative Strength Index (RSI) | 52.94 | 52.97 |
| Support Level | $16.84 | $29.95 |
| Resistance Level | $19.09 | $35.38 |
| Average True Range (ATR) | 0.65 | 2.02 |
| MACD | -0.06 | -0.11 |
| Stochastic Oscillator | 42.54 | 64.45 |
Price Performance
Historical ComparisonAbout LSBK Lake Shore Bancorp Inc.
Lake Shore Bancorp Inc operates as a savings and loan holding company. The bank's business consists of attracting retail deposits from the general public in the areas surrounding its branch offices and investing those deposits, together with funds generated from operations, in commercial real estate loans, one-to-four family residential mortgage loans, home equity lines of credit, and, to a lesser extent, commercial business loans, consumer loans, and investment securities. Its revenues are principally derived from interest earned on loans and investment securities.
About QNCX Quince Therapeutics Inc.
Quince Therapeutics Inc is a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases. Its proprietary AIDE technology is an inventive drug/device combination platform that uses an automated process to encapsulate a drug into a patient's own red blood cells. Its Phase 3 asset, eDSP, leverages the AIDE technology to encapsulate DSP into a patient's own red blood cells, and is targeted to treat a rare pediatric neurodegenerative disease, A-T.